Global Drug-Delivery Technology Market Projected to Reach $91.4B by 2030

The worldwide drug‑delivery technology market is set to expand from about $54.2 billion in 2025 to $60.3 billion in 2026, growing at an 11.1 % compound annual growth rate (CAGR), and could reach $91.4 billion by 2030. Growth is driven by rising prevalence of chronic diseases, increasing demand for patient‑friendly administration methods, and advances in targeted, sustained‑release and minimally invasive delivery systems.

Key players such as Merck & Co., AbbVie, Bayer, Sanofi, AstraZeneca and Novartis are expanding portfolios with products like pre‑filled injection devices and inhalation formulations. In the injection‑pen segment, manufacturers including Novo Nordisk, Sanofi, Eli Lilly, Ypsomed and Medtronic are focusing on diabetes, osteoporosis and fertility therapies, with a trend toward smart pens that connect to mobile devices.

Strategic moves include Molex’s acquisition of Vectura Group in January 2025, bolstering its inhalation‑device capabilities. North America remains the largest market, while Asia‑Pacific is expected to grow fastest due to expanding healthcare needs and technology adoption. Tariffs have raised component costs but also spurred local manufacturing, reinforcing supply‑chain resilience.